ClinicalTrials.gg
CompletedNCT04707573Updated Jun 28, 2022Results posted

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

A Phase 2 interventional study of Vadadustat in Chronic Kidney Disease, sponsored by Akebia Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-06-28.

Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 10 years 3 months after the study started (first participant enrolled Jul 2010, registered Nov 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing vadadustat in Renal Insufficiency, Chronic — none open to participants now, none under way, none of them phase 3. vadadustat · Renal Insufficiency, Chronic.

Enrollment
13th of 18
22 · median 94
Started
2010
with 1 other
Phase 2
6 of 18
none open now
Registered
14th of 18
by date
Lead sponsor
18 of 18
Akebia Therapeutics

Among the 18 studies testing vadadustat in Renal Insufficiency, Chronic, this one is the 13th largest by enrollment, is one of 2 that started in 2010, is one of 6 in phase 2, and was the 14th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 18 studies testing vadadustat in Renal Insufficiency, Chronic is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing vadadustat in Renal Insufficiency, Chronic as a file.
02

Study summary

This study was conducted to assess the pharmacokinetic (PK) profile, safety, and tolerability in participants with Stage 3 and 4 Chronic Kidney Disease (CKD) following a single oral dose of Vadadustat.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • CKD
  • CKD, Stage 3
  • CKD, Stage 4
  • Vadadustat
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 79 years of age, inclusive
  • Chronic Kidney Disease Stage 3 (Estimated [eGFR] 30 to 59 milliliters [mL]/minute) or Stage 4 participants (eGFR of \<30 mL/minute that were not yet on dialysis). eGFR was calculated using the Modification of Diet in Renal Disease (MDRD).
  • (Hb) \<13.5 grams per deciliter (g/dL) except for Polycystic Kidney Disease (PKD) participants, in which Hb was to be ≤14 g/dL
  • Transferrin saturation (TSAT) >12% and complete blood count (CBC) indicating normocytic red blood cell morphology, unless the medical monitor and investigator agreed that the participant was appropriate for this study
  • (AST) and alanine aminotransferase (ALT) ≤1.8 x (ULN)
  • Alkaline phosphatase ≤2 x ULN
  • ≤1.5 x ULN
  • Female participants were not pregnant or breastfeeding. Women of agreed to use an acceptable method of .
  • Non-vasectomized male participants agreed to use an acceptable method of contraception
  • Understood the procedures and requirements of the study and provided written and authorization for protected health information disclosure

Exclusion criteria

Exclusion Criteria:

  • Any medical or psychological condition that in the opinion of the Investigator would have interfered with the participant's ability to provide or comply with study instructions
  • Any or uncontrolled medical condition that in the opinion of the Investigator would have placed the participant at undo risk or would have compromised the interpretability of the findings in this study
  • A (BMI) of greater than 40
  • Seropositive for (HIV) or surface antigen
  • Seropositive for virus (HCV) antibodies unless , AST, tests were within normal limits
  • History of chronic liver disease
  • Uncontrolled hypertension (diastolic blood pressure [BP] > 110 millimeters of mercury [mm Hg] or systolic BP >190 mm Hg at screening)
  • Class III or IV congestive heart failure
  • Myocardial infarction, acute coronary syndrome, or stroke within 6 months of dosing
  • History of myelodysplastic syndrome
  • Participants known to have diabetic gastroparesis that was either symptomatic on therapy or was to therapy
  • Any history of in the previous 5 years except for curatively resected basal cell carcinoma of skin, squamous cell carcinoma of skin, cervical carcinoma in situ, or resected benign colonic polyps
  • Evidence of active infection unless the medical monitor and investigator agreed that the participant was appropriate for this study
  • History of rheumatoid arthritis or systemic lupus erythematosus (SLE) (History of osteoarthritis or gout did not exclude participants from eligibility in the study.)
  • Age-related macular degeneration (AMD), diabetic macular edema or active diabetic proliferative retinopathy that was likely to require treatment during the trial
  • History of deep vein thrombosis (DVT) that required active treatment. Superficial thrombosis was not excluded.
  • History of ongoing hemolysis or diagnosis of hemolytic syndrome
  • Known history of bone marrow fibrosis
  • History of hemosiderosis or hemochromatosis
  • Androgen therapy within 21 days from the last injection
  • Red blood cell transfusion within 12 weeks
  • Therapy with an erythropoiesis stimulating agent (ESA) such as human recombinant erythropoietin within the past 21 days
  • Intravenous iron supplementation within the past 21 days
  • Currently taking acetaminophen > 2.6 grams/day
  • History of prior organ transplantation, or stem cell or bone marrow transplantation
  • Alcohol consumption greater than 14 or more drinks per week within the past year (1 drink = 12 ounce [oz] beer, 5 oz wine, or 1.5 oz hard liquor.)
  • Use of an medication or participation in an investigational study within 30 days, or 5 half-lives of the investigational product, whichever was longer, preceding Day 1
  • Positive urine toxicology screen for a substance of abuse that had not been prescribed for the participant
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    CKD, Stage 3

    Participants with Stage 3 Chronic Kidney Disease (CKD) (Estimated Glomerular Filtration Rate \[eGFR\] 30 - 59 milliliters \[mL\]/minute) received a single 500 milligram (mg) oral dose of Vadadustat after fasting for at least 4 hours.

    Drug: Vadadustat

  • Experimental
    CKD, Stage 4

    Participants with Stage 4 CKD (eGFR \<30 mL/minute and not yet on dialysis) received a single 500 mg oral dose of Vadadustat after fasting for at least 4 hours.

    Drug: Vadadustat

Interventions

  • oral capsules

    Also known as: AKB-6548

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An Adverse Event (AE) was defined as any untoward, undesired, unplanned clinical event in the form of signs, symptoms, disease, or laboratory or physiological observations occurring in a human being participating in a clinical study following study medication administration, regardless of causal relationship. This also included any clinically significant worsening or re-occurrence of a pre-existing condition, or AE occurring from an overdose of a study drug whether accidental or intentional or AE occurring from abuse of study drug or that has been associated with the discontinuation of the use of study drug.

    Time frame: Up to Day 8

  2. Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values

    Parameters assessed for laboratory values included hematology, chemistry, urinalysis, and coagulation. The investigator was responsible for reviewing laboratory results for clinically significant changes.

    Time frame: Up to Day 8

  3. Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values

    Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing laboratory results for clinically significant changes. Number of participants with a clinically significant change from baseline in at least one of the assessed vital signs parameters is reported.

    Time frame: Up to Day 8

  4. Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings

    A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The investigator was responsible for reviewing laboratory results for clinical significance.

    Time frame: Up to Day 2

  5. Change From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval

    A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The parameters evaluated from the participant ECG trace included PR interval, QT interval, QRS interval, and QTc (corrected). The baseline was defined as Day 1 pre-dose measurement. If missing, the last measurement prior to dosing was used.

    Time frame: Baseline; Day 2

  6. Change From Baseline in Heart Rate

    The heart rate evaluation was performed after the participant had been resting comfortably in a supine position for approximately 10 minutes.

    Time frame: Baseline; Day 2

  7. Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings

    A baseline physical examination was performed at screening. Otherwise, abbreviated physical examinations were conducted and were to include heart, lung, and abdomen. The investigator was responsible for reviewing laboratory results for clinically significant changes.

    Time frame: Up to Day 8

  8. Geometric Mean Maximum Observed Plasma Concentration (Cmax) of AKB-6548

    Plasma samples were collected from the participants at the defined time points. Cmax was defined as the maximum observed plasma concentration. Cmax was calculated using the standard non-compartmental method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)

  9. Median Time to Reach Cmax (Tmax) of AKB-6548

    Plasma samples were collected from the participants at the defined time points. Tmax was defined as the time to reach maximum plasma concentration. Tmax was calculated using the standard non-compartmental method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)

  10. Mean Terminal Elimination Rate Constant (λz)

    Plasma samples were collected from the participants at the defined time points. λz was calculated using linear regression of the terminal linear portion of the log concentration vs. time curve. The parameter was calculated by linear least-squares regression analysis using three or more concentrations, excluding Cmax.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)

  11. Median Terminal Elimination Half-life (T½)

    Plasma samples were collected from the participants at the defined time points. T½ was defined as apparent terminal elimination half-life. T½ was calculated using the standard non-compartmental method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)

  12. Geometric Mean Area Under the Plasma Concentration-time Curve From 0 to Time T Over a Dosing Interval (AUC[0-T])

    Plasma samples were collected from the participants at the defined time points. AUC\[0-T) was defined as the area under the plasma concentration-time curve, from time=0 to the last measurable concentration (Ct) up to 24 hours, calculated by the linear trapezoidal method. AUC\[0-T) was calculated using the standard noncompartmental method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)

  13. Geometric Mean Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-∞])

    Plasma samples were collected from the participants at the defined time points. AUC\[0-∞\] was defined as the area under the plasma concentration-time curve from time=0 and extrapolated to infinity. AUC\[0-∞\] was calculated using the standard non-compartmental method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)

  14. Geometric Mean Apparent Oral Clearance (CL/F)

    Plasma samples were collected from the participants at the defined time points. CL/F was defined as apparent oral clearance, calculated as Dose/AUC(0-inf). CL/F was calculated using the standard non-compartmental method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)

  15. Geometric Mean Apparent Volume of Distribution During the Terminal Phase (Vd/F)

    Plasma samples were collected from the participants at the defined time points. Vd/F was defined as the apparent volume of distribution during the terminal phase, calculated as Dose/\[λz \* AUC(0-inf)\]. Vd/F was calculated using the standard non-compartmental method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)

Secondary outcomes

  1. Change From Baseline in Mean Erythropoietin (EPO)

    The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values.

    Time frame: Baseline; 8, 12, and 24 hours post-dose

Other outcomes

  1. Exploratory: Change From Baseline in Hepcidin at 24 Hours

    Time frame: Baseline; 24 hours post-dose

  2. Exploratory: Change From Baseline in Vascular Endothelial Growth Factor (VEGF) at 24 Hours

    Time frame: Baseline; 24 hours post-dose

  3. Exploratory: Change From Baseline in Transferrin at 24 Hours

    Time frame: Baseline; 24 hours post-dose

  4. Exploratory: Change From Baseline in Cystatin-C at 24 Hours

    Time frame: Baseline; 24 hours post -dose

  5. Exploratory: Change From Baseline in Adiponectin at 24 Hours

    Time frame: Baseline; 24 hours post -dose

  6. Exploratory: Change From Baseline in Ferritin at 24 Hours

    Time frame: Baseline; 24 hours post-dose

07

Results

Posted May 17, 2022

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Started1012
Completed1012
Not completed00

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An Adverse Event (AE) was defined as any untoward, undesired, unplanned clinical event in the form of signs, symptoms, disease, or laboratory or physiological observations occurring in a human being participating in a clinical study following study medication administration, regardless of causal relationship. This also included any clinically significant worsening or re-occurrence of a pre-existing condition, or AE occurring from an overdose of a study drug whether accidental or intentional or AE occurring from abuse of study drug or that has been associated with the discontinuation of the use of study drug.

Time frame:
Up to Day 8
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Number of Participants With Treatment-emergent Adverse Events (TEAEs)62
PrimaryNumber of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values

Parameters assessed for laboratory values included hematology, chemistry, urinalysis, and coagulation. The investigator was responsible for reviewing laboratory results for clinically significant changes.

Time frame:
Up to Day 8
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
ParticipantsCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Urinalysis00
Hematology00
Serum chemistry10
Coagulation00
PrimaryNumber of Participants With Clinically Significant Changes From Baseline in Vital Sign Values

Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing laboratory results for clinically significant changes. Number of participants with a clinically significant change from baseline in at least one of the assessed vital signs parameters is reported.

Time frame:
Up to Day 8
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values
ParticipantsCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values20
PrimaryNumber of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings

A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The investigator was responsible for reviewing laboratory results for clinical significance.

Time frame:
Up to Day 2
Reported as:
Count of participants · Participants
Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings
ParticipantsCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings00
PrimaryChange From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval

A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The parameters evaluated from the participant ECG trace included PR interval, QT interval, QRS interval, and QTc (corrected). The baseline was defined as Day 1 pre-dose measurement. If missing, the last measurement prior to dosing was used.

Time frame:
Baseline; Day 2
Reported as:
Mean · Milliseconds
Change From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval
MillisecondsCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Baseline PR interval178.8 ± 44.2182.5 ± 24.2
Change from Baseline at Day 2 PR interval-12.4 ± 28.4-3.5 ± 5.5
Baseline QRS interval98.8 ± 20.797.7 ± 26.0
Change from Baseline at Day 2 QRS interval-0.8 ± 3.20.0 ± 5.4
Baseline QT interval427.2 ± 22.0426.5 ± 39.7
Change from Baseline at Day 2 QT interval-13.8 ± 21.8-2.3 ± 16.7
Baseline QTc interval423.5 ± 22.8439.5 ± 35.8
Change from Baseline at Day 2 QTc interval3.1 ± 10.22.0 ± 18.2
PrimaryChange From Baseline in Heart Rate

The heart rate evaluation was performed after the participant had been resting comfortably in a supine position for approximately 10 minutes.

Time frame:
Baseline; Day 2
Reported as:
Mean · Beats per minute
Change From Baseline in Heart Rate
Beats per minuteCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Baseline59.8 ± 9.064.3 ± 5.6
Change from Baseline at Day 25.2 ± 6.31.8 ± 3.7
PrimaryNumber of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings

A baseline physical examination was performed at screening. Otherwise, abbreviated physical examinations were conducted and were to include heart, lung, and abdomen. The investigator was responsible for reviewing laboratory results for clinically significant changes.

Time frame:
Up to Day 8
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings
ParticipantsCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings00
PrimaryGeometric Mean Maximum Observed Plasma Concentration (Cmax) of AKB-6548

Plasma samples were collected from the participants at the defined time points. Cmax was defined as the maximum observed plasma concentration. Cmax was calculated using the standard non-compartmental method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Reported as:
Geometric mean · Micrograms per millilitre (mcg/mL)
Geometric Mean Maximum Observed Plasma Concentration (Cmax) of AKB-6548
Micrograms per millilitre (mcg/mL)Cohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Geometric Mean Maximum Observed Plasma Concentration (Cmax) of AKB-654842.486 ± 36.31440.952 ± 35.022
PrimaryMedian Time to Reach Cmax (Tmax) of AKB-6548

Plasma samples were collected from the participants at the defined time points. Tmax was defined as the time to reach maximum plasma concentration. Tmax was calculated using the standard non-compartmental method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Reported as:
Median · Hours
Median Time to Reach Cmax (Tmax) of AKB-6548
HoursCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Median Time to Reach Cmax (Tmax) of AKB-65485.5 (1.0 to 8.0)5.0 (2.0 to 6.0)
PrimaryMean Terminal Elimination Rate Constant (λz)

Plasma samples were collected from the participants at the defined time points. λz was calculated using linear regression of the terminal linear portion of the log concentration vs. time curve. The parameter was calculated by linear least-squares regression analysis using three or more concentrations, excluding Cmax.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Reported as:
Mean · 1/Hour
Mean Terminal Elimination Rate Constant (λz)
1/HourCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Mean Terminal Elimination Rate Constant (λz)0.105 ± 0.0290.086 ± 0.020
PrimaryMedian Terminal Elimination Half-life (T½)

Plasma samples were collected from the participants at the defined time points. T½ was defined as apparent terminal elimination half-life. T½ was calculated using the standard non-compartmental method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Reported as:
Median · Hours
Median Terminal Elimination Half-life (T½)
HoursCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Median Terminal Elimination Half-life (T½)7.070 (4.530 to 9.930)7.530 (5.680 to 12.270)
PrimaryGeometric Mean Area Under the Plasma Concentration-time Curve From 0 to Time T Over a Dosing Interval (AUC[0-T])

Plasma samples were collected from the participants at the defined time points. AUC\[0-T) was defined as the area under the plasma concentration-time curve, from time=0 to the last measurable concentration (Ct) up to 24 hours, calculated by the linear trapezoidal method. AUC\[0-T) was calculated using the standard noncompartmental method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Reported as:
Geometric mean · mcg*hr/mL
Geometric Mean Area Under the Plasma Concentration-time Curve From 0 to Time T Over a Dosing Interval (AUC[0-T])
mcg*hr/mLCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Geometric Mean Area Under the Plasma Concentration-time Curve From 0 to Time T Over a Dosing Interval (AUC[0-T])441.651 ± 36.162448.399 ± 34.081
PrimaryGeometric Mean Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-∞])

Plasma samples were collected from the participants at the defined time points. AUC\[0-∞\] was defined as the area under the plasma concentration-time curve from time=0 and extrapolated to infinity. AUC\[0-∞\] was calculated using the standard non-compartmental method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Reported as:
Geometric mean · mcg*hr/mL
Geometric Mean Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-∞])
mcg*hr/mLCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Geometric Mean Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-∞])503.688 ± 41.671535.813 ± 40.320
PrimaryGeometric Mean Apparent Oral Clearance (CL/F)

Plasma samples were collected from the participants at the defined time points. CL/F was defined as apparent oral clearance, calculated as Dose/AUC(0-inf). CL/F was calculated using the standard non-compartmental method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Reported as:
Geometric mean · Litre per Hour (L/hr)
Geometric Mean Apparent Oral Clearance (CL/F)
Litre per Hour (L/hr)Cohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Geometric Mean Apparent Oral Clearance (CL/F)0.995 ± 41.6830.934 ± 40.324
PrimaryGeometric Mean Apparent Volume of Distribution During the Terminal Phase (Vd/F)

Plasma samples were collected from the participants at the defined time points. Vd/F was defined as the apparent volume of distribution during the terminal phase, calculated as Dose/\[λz \* AUC(0-inf)\]. Vd/F was calculated using the standard non-compartmental method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose (Day 2)
Reported as:
Geometric mean · Liter
Geometric Mean Apparent Volume of Distribution During the Terminal Phase (Vd/F)
LiterCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Geometric Mean Apparent Volume of Distribution During the Terminal Phase (Vd/F)9.863 ± 20.47911.105 ± 31.747
SecondaryChange From Baseline in Mean Erythropoietin (EPO)

The change from baseline was calculated by subtracting the baseline value from the individual post-dose visit values.

Time frame:
Baseline; 8, 12, and 24 hours post-dose
Reported as:
Mean · milli-international units per milliliter
Change From Baseline in Mean Erythropoietin (EPO)
milli-international units per milliliterCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
Baseline23.14 ± 15.0021.65 ± 15.84
8 Hours Post-dose6.16 ± 9.9712.07 ± 11.13
12 Hours Post-dose5.41 ± 7.6611.09 ± 8.71
24 Hours Post-dose-1.44 ± 5.712.08 ± 5.57
Other pre-specifiedExploratory: Change From Baseline in Hepcidin at 24 Hours
Time frame:
Baseline; 24 hours post-dose

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Change From Baseline in Vascular Endothelial Growth Factor (VEGF) at 24 Hours
Time frame:
Baseline; 24 hours post-dose

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Change From Baseline in Transferrin at 24 Hours
Time frame:
Baseline; 24 hours post-dose

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Change From Baseline in Cystatin-C at 24 Hours
Time frame:
Baseline; 24 hours post -dose

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Change From Baseline in Adiponectin at 24 Hours
Time frame:
Baseline; 24 hours post -dose

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Change From Baseline in Ferritin at 24 Hours
Time frame:
Baseline; 24 hours post-dose

Results for this outcome have not been posted.

Adverse events

Collected over Up to Day 8. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: CKD Stage 3 Vadadustat0/10 (0%)0/10 (0%)6/10 (60%)
Cohort 2: CKD Stage 4 Vadadustat0/12 (0%)0/12 (0%)2/12 (16.7%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventCohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 Vadadustat
NauseaGastrointestinal disorders2/100/12
TachycardiaCardiac disorders1/100/12
VomitingGastrointestinal disorders1/100/12
PyrexiaGeneral disorders1/100/12
Upper Respiratory Tract InfectionInfections and infestations1/100/12
HypomagnesaemiaMetabolism and nutrition disorders1/100/12
MyalgiaMusculoskeletal and connective tissue disorders1/100/12
Pain in ExtremityMusculoskeletal and connective tissue disorders1/100/12
Skin PapillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/100/12
HeadacheNervous system disorders1/100/12

Baseline characteristics

Enrolled Population: The enrolled population consisted of all participants who were enrolled in the study.

Age, Continuous
Age, Continuous(years)Cohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 VadadustatTotal
Mean63.0 ± 12.964.4 ± 10.063.8 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 VadadustatTotal
Female5813
Male549
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 VadadustatTotal
Hispanic or Latino000
Not Hispanic or Latino101222
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 VadadustatTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White91120
More than one race000
Unknown or Not Reported000
Estimated Glomerular Filtration Rate
Estimated Glomerular Filtration Rate(mL/min/1.73m^2)Cohort 1: CKD Stage 3 VadadustatCohort 2: CKD Stage 4 VadadustatTotal
Mean45.22 ± 8.5424.39 ± 3.3133.86 ± 12.23
08

Study locations

2 sites
  • Research Site
    Saint Paul, Minnesota 55114, United States
  • Research Site
    Knoxville, Tennessee 37920, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2010 to primary completion in Sep 2010, 2 months.

Results were first posted in May 2022, 11 years 7 months after primary completion. A results delay was requested in Jan 2021.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 2 months is below that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2020
First posted
Jan 13, 2021
StartActual
Jul 8, 2010
Primary completionActual
Sep 24, 2010
CompletionActual
Sep 24, 2010
Results delay requested
Jan 12, 2021
Results first posted
May 17, 2022
Last update
Jun 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04707573
Responsible party
Sponsor
First posted
Jan 13, 2021
Start date
Jul 8, 2010
Primary completion
Sep 24, 2010
Completion
Sep 24, 2010
Results posted
May 17, 2022
Last update
Jun 28, 2022

Study contacts

Chief Medical Officer
study director · Akebia Therapeutics Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion